ADC Target Strategy Radar
Map oncology ADC targets by clinical crowding, clinical maturity, sponsor competition, patent-density signals, and recent momentum.
Built from ClinicalTrials.gov and a conservative patent-signal layer. Outputs are designed to help teams prioritize which ADC targets deserve expert IP and BD attention — not to replace FTO analysis or target-selection advice.
Is this ADC target still strategically attractive?
Or is it already crowded, mature, patent-heavy, or low-signal? This module helps teams answer that question using public trial registries and conservative patent-density signals — before engaging IP counsel on a costly FTO analysis.
Target users
- ADC biotech founders selecting a first or next target
- Pharma BD teams evaluating in-licensing candidates
- Oncology investors assessing competitive dynamics
- Competitive-intelligence teams tracking target spaces
- IP strategy groups prioritizing freedom-to-operate review
- Target-selection teams benchmarking across programs
Tracked ADC oncology targets
The Oncology edition maps curated ADC target–modality pairs across the following oncology-relevant targets:
- HER2 / ERBB2
- TROP2 / TACSTD2
- B7-H3 / CD276
- Nectin-4
- CLDN18.2
- FRα / FOLR1
- c-MET
- ROR1
- GPC3
- PSMA
- BCMA
- DLL3
Additional targets are included in the full edition. Target coverage expands as new trial activity is detected.
How teams use this module
- Compare B7-H3 versus CLDN18.2 ADC clinical activity and sponsor competition
- Identify patent-heavy but clinically light targets that may warrant IP review before program launch
- Map sponsor activity across ADC targets to find white space or congested areas
- Track fast-emerging ADC targets entering active trial phases
- Monitor new trials and patent-density signal changes monthly
- Generate a custom target or tumor-type ADC scan for BD or IP diligence
Oncology Edition
Map curated ADC oncology targets across trial activity, sponsor diversity, patent-density signals, and conservative strategic-position labels.
- Curated target universe across 20+ oncology-relevant ADC targets
- Target pages, sponsor pages, and source-linked evidence paths
- Deterministic labels with manual-review-first QA
- Built for screening, not legal or commercial conclusions
Receive ADC Target Updates by Email
Tell us which ADC targets and tumor types matter to your team. We use this form for email updates, CSV delivery preferences, and custom scan follow-up.